gefitinib and etoposide
gefitinib has been researched along with etoposide in 30 studies
Compound Research Comparison
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (etoposide) | Trials (etoposide) | Recent Studies (post-2010) (etoposide) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 18,306 | 3,693 | 4,900 |
Protein Interaction Comparison
Protein | Taxonomy | gefitinib (IC50) | etoposide (IC50) |
---|---|---|---|
nuclear receptor coactivator 1 isoform 1 [Homo sapiens] | Homo sapiens (human) | 1.153 | |
nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 1.4284 | |
Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 3.187 | |
Caspase-3 | Homo sapiens (human) | 1 | |
DNA topoisomerase 2-beta | Homo sapiens (human) | 0.4299 | |
Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 4.18 |
Research
Studies (30)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 14 (46.67) | 29.6817 |
2010's | 12 (40.00) | 24.3611 |
2020's | 4 (13.33) | 2.80 |
Authors
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Bansal, R; Malhotra, A | 1 |
Bunn, PA; Chan, DC; Chan, KK; Covey, JM; Feng, WY; Gera, L; Helfrich, B; Stewart, JM; Zhao, TL | 1 |
Shimizu, E | 1 |
Caplin, M; Friedmann, B; Hartley, JA; Hochhauser, D | 1 |
Fujimoto, N; Fujiwara, K; Hamazaki, S; Kiura, K; Kozuki, T; Mizobuchi, K; Shiomi, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
Cheng, AL; Chu, YC; Huang, CJ; Whang-Peng, J; Yang, CH; Yang, CS; Yang, PC | 1 |
Ashworth, A; Caplin, M; Friedmann, BJ; Hartley, JA; Hochhauser, D; Lord, CJ; Savic, B; Shah, T | 1 |
Iwashige, A; Kagami, S; Tsukada, J; Uramoto, H | 1 |
Katakami, N | 1 |
Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Venkatraman, G | 1 |
Memon, AA; Munk, M; Nexo, E; Sorensen, BS | 1 |
Yoneda, S | 1 |
Albain, KS; Chansky, K; Crowley, JJ; Gandara, DR; Gaspar, LE; Jett, J; Kelly, K; Lau, DH; Ung, YC | 1 |
Guo, Y; Jiang, X; Li, Z; Wang, G; Xi, Z; Yan, B; Yao, Y | 1 |
Baxter, RC; Lin, MZ; Martin, JL; Marzec, KA | 1 |
Bhosle, J; Hartley, JA; Hochhauser, D; Kiakos, K; Makris, A; Porter, AC; Wu, J | 1 |
Yano, S | 1 |
Apte, RN; Kogan-Zviagin, I; Peleg, R; Priel, E; Romzova, M | 1 |
Gao, W; Liu, Z; Lockman, PR; Mohammad, A; Pinti, MV; Saralkar, PA; Shah, N; Sprowls, SA; Tallman, RM; Vickers, SD | 1 |
Bal, A; Gupta, N; Gupta, P; Khosla, D; Shastri, M; Singh, N; Srinivasan, R | 1 |
Li, S; Li, Z; Liu, S; Wang, Z; Zhao, F | 1 |
Reviews
5 review(s) available for gefitinib and etoposide
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Quinazolines | 2021 |
[Molecular pathogenesis of lung cancers and the preservative therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Cycle Proteins; Cisplatin; Enzyme Inhibitors; Etoposide; Gefitinib; Gene Targeting; Genes, bcl-2; Genes, p53; Genetic Therapy; Humans; Lung Neoplasms; Mass Screening; Mutation; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant | 2004 |
[Chemotherapy for lung cancer patients].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Etoposide; Evidence-Based Medicine; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2006 |
[Programs for continuing medical education: B session; 4. Progress in lung cancer therapy].
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Crizotinib; Drug Discovery; Education, Medical, Continuing; Erlotinib Hydrochloride; Etoposide; Gefitinib; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma | 2014 |
Trials
1 trial(s) available for gefitinib and etoposide
Article | Year |
---|---|
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
Other Studies
24 other study(ies) available for gefitinib and etoposide
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Bradykinin; Bradykinin Receptor Antagonists; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; Cisplatin; Dimerization; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Etoposide; Gefitinib; Humans; Infusion Pumps; Injections, Intralesional; Injections, Intraperitoneal; Injections, Subcutaneous; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Oligopeptides; Paclitaxel; Quinazolines; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2002 |
Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839).
Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Chromones; Cisplatin; Comet Assay; DNA Damage; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Etoposide; Gefitinib; Humans; Melphalan; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Signal Transduction; Time Factors | 2004 |
Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroendocrine Tumors; Quinazolines; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Failure; Treatment Outcome | 2005 |
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment.
Topics: Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Nucleus; Cisplatin; Cytosol; DNA; DNA-Activated Protein Kinase; ErbB Receptors; Etoposide; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; RNA, Small Interfering; Wortmannin | 2006 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Proliferation; Cells, Cultured; Ceramides; Cytochromes c; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Etoposide; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; Male; Membrane Potential, Mitochondrial; Neoplasms, Hormone-Dependent; Prostate; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen | 2007 |
Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; ErbB Receptors; Etoposide; Gefitinib; Humans; Quinazolines; Treatment Outcome; Urinary Bladder Neoplasms | 2007 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
Mitochondrially localized EGFR is independent of its endocytosis and associates with cell viability.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Cell Survival; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Etoposide; Gefitinib; Green Fluorescent Proteins; Humans; Immunoblotting; Microscopy, Immunoelectron; Mitochondria; Mitochondrial Proteins; Mutation; Protein Transport; Quinazolines | 2010 |
The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Survival; DNA Damage; DNA Repair; DNA-Activated Protein Kinase; Doxorubicin; ErbB Receptors; Etoposide; Female; Gefitinib; Humans; Insulin-Like Growth Factor Binding Protein 3; Membrane Microdomains; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines | 2014 |
Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gefitinib; Gene Expression Regulation, Neoplastic; Histones; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2013 |
Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors.
Topics: Animals; Antigens, Surface; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Topoisomerases; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Synergism; Enzyme Activation; Etoposide; Female; Gefitinib; Humans; Immunophenotyping; MCF-7 Cells; Mice; Neoplastic Stem Cells; Quinazolines; Spheroids, Cellular; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2014 |
Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Etoposide; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Pemetrexed; Xenograft Model Antitumor Assays | 2020 |
Sequential small cell transformation and T790M mutation in an epidermal growth factor-mutant lung adenocarcinoma: A rare occurrence with significant management implications.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carboplatin; Carcinoma, Small Cell; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Etoposide; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Identifying a lactic acid metabolism-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Etoposide; Gefitinib; Humans; Immunologic Factors; Immunotherapy; Lactic Acid; Lung Neoplasms; Prognosis; Reproducibility of Results; Tumor Microenvironment | 2022 |